Trial Profile
A study To Evaluate The Efficacy Of Nintedanib On Cytokine/Chemokine Production By Alveolar Macrophages In Patients With Interstitial Lung Diseases.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases
- Focus Therapeutic Use
- 18 Aug 2015 New trial record